Answers are grounded in this paper and cite their sources.
) with significant improved survivability (90%) until 120 h of incubation. Results showed that RuPIP-Olap@ZIF8-FA did not cause significant malformations, even at elevated concentrations, and did not present aggregation issues toward healthy embryos. These findings establish RuPIP-Olap@ZIF-8-FA as a promising dual-drug nanocarrier capable of targeted delivery, pH-triggered release, and distinct therapeutic pathways. Its high loading efficiency, simplicity, and improved safety profile highlight its strong potential for advancement toward clinical translation.
No takes yet. Share an insight, caveat, or question.
Sadeq et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: